US › Healthcare

iBio, Inc. Common Stock (IBIO)

US · Healthcare · Biotechnology

$1.46+2.82%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-7.7M
Profit YoY
-59.0%
EPS
$-0.06
EPS estimate
$-0.06

EPS came in at -0.06 against a street estimate of -0.06 — a miss of 2.1%.

Key statistics

Market cap
$69.5M
Forward P/E
0.0
P/B
0.90
Book value
$2.25
EPS (TTM)
$-0.56
52-week high
$3.82
52-week low
$0.56
50-day MA
$1.62
200-day MA
$1.82
Beta
1.27

Analyst view

Analysts rate iBio, Inc. Common Stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $5.40.

Shareholding

Insiders
1.71%
Institutions
48.61%

Largest institutional holders

FundStake
Affinity Asset Advisors, LLC6.25%
Frazier Life Sciences Management, L.P.3.93%
EcoR1 Capital, LLC3.19%
Millennium Management LLC3.12%
Logos Global Management LP2.62%
Vanguard Capital Management, LLC2.19%
Balyasny Asset Management LLC2.04%
Ikarian Capital, LLC1.93%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for iBio, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.